Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $932000.0.

  • Voyager Therapeutics' Depreciation & Amortization (CF) fell 1766.78% to $932000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 2043.52%. This contributed to the annual value of $4.7 million for FY2024, which is 653.01% up from last year.
  • Per Voyager Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $932000.0 for Q3 2025, which was down 1766.78% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q1 2022 and a low of $843000.0 during Q4 2022
  • In the last 5 years, Voyager Therapeutics' Depreciation & Amortization (CF) had a median value of $1.2 million in 2021 and averaged $1.2 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 12072.21% in 2022, then plummeted by 6177.1% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Depreciation & Amortization (CF) stood at $1.5 million in 2021, then plummeted by 44.43% to $843000.0 in 2022, then surged by 58.36% to $1.3 million in 2023, then decreased by 24.27% to $1.0 million in 2024, then decreased by 7.81% to $932000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $932000.0 in Q3 2025, compared to $1.1 million in Q2 2025 and $1.0 million in Q1 2025.